A Child with Chronic Mucocutaneous Candidiasis Harbors a Novel Gain-of-Function Mutation in STAT1
Journal of Clinical Immunology · 2025
DOI: 10.1007/s10875-025-01937-4 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Immunology, 2025. Verfasst von Yang Xiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250000, Shandong Province, P.…. Hauptthemen laut MEDLINE: Candidiasis, Chronic Mucocutaneous, Gain of Function Mutation, STAT1 Transcription Factor. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
OBJECTIVE: Germline heterozygous gain-of-function (GOF) mutations in STAT1 impair IL-17-mediated immunity, resulting in carriers' susceptibility to chronic mucocutaneous candidiasis (CMC). JAK inhibitors have shown therapeutic effectiveness in patients with STAT1-GOF mutations. METHODS: The mutation was detected using whole-exome sequencing (WES) and confirmed by Sanger sequencing. The functional impact of the mutation was verified by luciferase reporter assay. The phosphorylation level of STAT1 in patient cells, the phenotyping of leukocyte subtypes, and serum cytokine levels were determined by flow cytometry. RESULTS: The patient with CMC harbors a heterozygous missense mutation in STAT1 (c.1078G > C, p.V360L). This mutation was functionally validated as a GOF mutation based on functional analysis of the variant and enhanced phosphorylation upon IFN-γ stimulation in the patient's cells. Additionally, the patient demonstrated a decreased proportion of CD4 + T cells, NK cells, and Th17 cells. Flow cytometry analysis revealed a significant decrease in the expression of IL-17 A in CD4 + T cells from the patient. Serological test results showed that the patient's IgM level was decreased, while the levels of IL-2, IL-5, IL-6 and TNF-α were elevated. Topical application of ruxolitinib demonstrated therapeutic efficacy. CONCLUSIONS: The present study reports a pediatric patient with CMC who carries a novel GOF mutation in STAT1. This mutation may impair IL-17 immunity, which could potentially increase the patient's susceptibility to CMC. However, further research is needed to elucidate the underlying mechanism. Although ruxolitinib shows potential as a therapeutic option for CMC, its clinical efficacy requires further validation through experimental studies and long-term patient follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250000, Shandong Province, P.R. China.
- Department of Dermatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250000, Shandong Province, P.R. China.
- Laboratory of Human Immunology and Infectious Diseases, Institute of Immunology and Translational Medicine, Chang Gung University, Taoyuan, Taiwan.
- Division of Immunology, Rheumatology, and Allergy, Department of Pediatrics, Hsinchu Municipal MacKay Children's Hospital, Hsinchu, Taiwan.
- Center for Molecular and Clinical Immunology, Chang Gung University, Taoyuan, Taiwan.
- Laboratory of Human Immunology and Infectious Diseases, Institute of Immunology and Translational Medicine, Chang Gung University, Taoyuan, Taiwan. clku@cgu.edu.tw.
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Xiang, Y., Sun, S., Wang, H., Lo, C. C., Wu, J., Lei, W. T., Li, F., Liu, X., Dang, N., Ku, C. L., & Guo, J. (2025). A Child with Chronic Mucocutaneous Candidiasis Harbors a Novel Gain-of-Function Mutation in STAT1. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-025-01937-4
Vancouver
Xiang Y, Sun S, Wang H, Lo CC, Wu J, Lei WT, et al. A Child with Chronic Mucocutaneous Candidiasis Harbors a Novel Gain-of-Function Mutation in STAT1. Journal of Clinical Immunology. 2025. doi:10.1007/s10875-025-01937-4
BibTeX
@article{Xiang2025,
author = {Xiang, Yang and Sun, Shuo and Wang, Hong and Lo, Chia-Chi and Wu, Jie and Lei, Wei-Te and Li, Fengming and Liu, Xiaodong and Dang, Ningning and Ku, Cheng-Lung and Guo, Jing},
title = {A Child with Chronic Mucocutaneous Candidiasis Harbors a Novel Gain-of-Function Mutation in STAT1},
journal = {Journal of Clinical Immunology},
year = {2025},
doi = {10.1007/s10875-025-01937-4}
}
EUVIMED